Datamonitor plc, Charles House, 108-110 Finchley Road, London NW3 5JJ, UK, Tel: +44 (0)20 7675 7000, Fax: +44 (0)20 7675 7500, E-mail: apavlou@datamonitor.com

Received 3 March 2004.

Abstract

Datamonitor's recombinant protein analytical framework shows that the sector with 77 marketed and 104 pipeline products will reach maturity undisturbed from potential biogeneric threat. It will see its value growing from US$35.8bn in 2004 to US$53bn in 2010 with a compound annual growth rate of no higher than 7 per cent. In terms of protein class focus, erythropoietins will continue to lead sales with 2010 sales of US$11.4; almost one-fifth of the sector's value. Haematology diabetes/endocrinology and oncology will continue to be the key therapy areas with 2010 sales of US$13.4bn, US$9.5bn and US$8bn, respectively. Amgen's blockbusters Enbrel, Neulasta and Aranesp will be the sector's key leading blockbusters, with combined 2010 sales of more than US$10.8bn, capturing one-fifth of the sector's value.